Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Investor Presentation (March 2020)
15 slides from Streamex's investor presentation, Mar 30, 2020
Slide 1: ViralClear Pharmaceuticals Corporate Presentation Spring 2020
X%& ViralClear ViralClear Pharmaceuticals, Inc. Corporate Presentation Spring 2020
Slide 2: Disclaimer
Disclaimer % ViralClear This presentation contains forward-looking statements including statements that address aotivities, events or developments that ViralClear Pharmaceuticals, Inc, (‘ViralClear’)expects, believes or anticipates will or may ocour in the future, such as predictions of financial pe
Slide 3: Highlights
Highlights % ViralClear Fhe Developed Vicromax — a powerful, broad spectrum, orally taken, anti-viral agent to target COVID-19 Product has already undergone extensive animal testing and human clinical experience (134 treated patients) in other applications Proven to be highly active against COVID-19
Slide 4: Our Goal
Our Goal % ViralClear To eliminate the COVID-19 pandemic and offer a preventive solution to future viral threats
Slide 5: The Problem: COVID-19 Worldwide Pandemic 2020
The Problem COVID-19 Worldwide Pandemic 2020 % ViralClear Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in 2019 in Wuhan, China, and has since spread globally, resulting in the 201
Slide 6: % ViralClear
% ViralClear An estimated 40% to 70% of the world’s population may be infected with COVID-19 in the coming year”.
Slide 7: Total Cases of COVID-19
Total Cases of COVID-19 3 ViralClear near ——_ogaritrmic logarithmic Total Cases outside of China Total Cases near Scale) (near Seale) 300% 00% March 22 ® 4 . ~ Cases: 378,860 2 $ sok 8 200% 8 2 B co: POPS OF I LO SO DS oS 8 0 2 LPP KH EH EHO EEE KM KK SF vy source: Wordometr- mma owe: Workomete- man
Slide 8: Our Highly Effective Solution
Our Highly Effective Solution % ViralClear + ViralClear has developed Vicromax - a small- Key Advantages: molecule, oral anti-viral for the treatment of COVID-19 infections 2 O.o imei (alfoyfel + Laboratory tests indicate very good activity el against COVID-19 if Wi . . Phase 2 ready; tested in Give
Slide 9: Our Product: Vicromax
Our Product: Vicromax* A novel inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme responsible for stimulating the production of lymphocytes Has the potential to exert direct anti-viral activity, as well as immune response modifier An oral drug, formulated into softgels Available in
Slide 10: Current Competition
Current Competition « Anti-virals ¢ Anti-inflammatories * Vaccines Because of the immediate need for highly effective therapies, only anti-viral agents and anti- inflammatory medications that can enter the clinic in less than six months can address the current pandemic. Our solution is one of the mo
Slide 11: Business Objectives
Business Objectives % ViralClear @ e@ Cs) © Develop highly Initially and with Rapidly scale up Sustained Work with effective the utmost commercial revenue and governments products that urgency, production to profit growth to and public eliminate introduce into meet the current fund R&D and a health
Slide 12: Lifecycle Management Focused on COVID-19
Lifecycle Management Focused on COVID-19 % ViralClear duct pre-clinical r population on combination ther L_, Initial focus on symptomatic, hospitalized COVID-19 patients * Positive results should lead to initial approval Better refinement to understand the ICs for the drug Test in tissue culture and
Slide 13: Short-Term Milestones Until Clinical Data
Short-Term Milestones Until Clinical Data 3 viraiclear Apr. IEW, June July Aug Sep. Oct. Nov. Dec. 2020 2020 2020 2020 2020 2020 2020 2020 File IND ka application Begin Phase 2 tial | Beg pa a clinical trial Deliver | | topline data Depending on data, next steps TBD
Slide 14: Experienced Management Team
Experienced Management Team Nick Spring, BSc (Hons), DipM, MCIM — Chief Executive Officer Experienced executive with 35+ years of relevant experience in the life sciences industry Forrner executive at Merck; led the worldwide franchise for live viral hurnan vaccines; led planning team for the launch
Slide 15: Contact
3% ViralClear Contact: /\ Nick Spring, CEO &) Email: nspring@biosigtech.com oO Phone: +1 (215) 962-0375
BioSig Technologies — Investor Presentation (March 2020) on 6ix